Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Summary

The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab. Regorafenib is FDA approved administered as monotherapy during the study. 22 total patients are expected to participate in this study. Even though a participant may meet all the criteria for participation, it is possible that they will not be enrolled in this study.

Timeline

Start

2019-07-31

Primary completion

2024-03-20

Completion

2024-03-20

Publications

• Lucas A, Peereboom D, Rauf Y, Li H, Hanlon J, Ahluwalia M. Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab. Neurooncol Adv. 2026 Jun 9;8(1):vdag144. doi: 10.1093/noajnl/vdag144. eCollection 2026 Jan-Dec.

Drugs

Indications